TYMS and non-small cell lung carcinoma: Subgroup analysis based on detecting method showed that low/negative expression of TYMS detected by IHC was significantly associated with longer progression free survival in advanced NSCLC patients treated with pemetrexed-based chemotherapy (HR 0.49, 95%CI [0.40, 0.60] P<0.00001; Figure 4).